


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF FIRST SUBJECT DOSING OF CLASS 1 INNOVATIVE DRUG TQB6411
(EGFR/c-MET BISPECIFIC ADC)

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group’s self-developed Class 1 innovative drug, TQB6411 for injection (EGFR/c-Met bispecific ADC), has recently completed the first subject enrollment and successful dosing in a Phase I clinical study in the PRC. TQB6411 was approved by the National Medical Products Administration (NMPA) of the PRC on 13 June to commence clinical trials, intended for the treatment of advanced malignant tumors. The development progress of TQB6411 is currently among the global leading cohort, with similar drugs worldwide also in Phase I.

TQB6411 is a bispecific ADC targeting EGFR/c-Met. Mutations or abnormally high expression of EGFR and c-MET are found in various tumors including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma^[1, 2]. Therefore, EGFR/c-MET bispecific ADC have broad application potential.

TQB6411 has completed systematic pharmacological, pharmacokinetic and preclinical safety evaluations. Preclinical in vivo pharmacodynamic studies have demonstrated a clear anti-tumor mechanism of action, showing anti-tumor activity in animal models with varying expression levels and resistance profiles of EGFR and c-Met. TQB6411 exhibits pharmacokinetic characteristics consistent with ADC drugs. Its primary toxic reactions are attributable to the pharmacological effects of the target and the small molecule toxin, with manageable toxicity risks. The current Phase I clinical trial will focus on evaluating its safety, tolerability, pharmacokinetics and preliminary efficacy in humans.

In addition to TQB6411, the Group also has TQB2102 (HER2 bispecific ADC) in Phase III, LM-302 (CLDN18.2 ADC) in Phase III, LM-305 (GPRC5D ADC) in Phase I/II, TQB2101 (ROR1 ADC) in Phase I, and dozens of ADC projects in preclinical development, which are expected to enter clinical stages progressively over the next 1–2 years.

Sources:

- [1] Karlsen EA, Kahler S, Tefay J, et al. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. *Cells*, 2021, 10(5): 1206.
- [2] Lai X, Dong Q, Xu F, et al. Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer. *J Gastrointest Oncol*, 2021, 12(5): 2203-2210.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 22 July 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.